You are here: Welcome » Marcie Glicksman

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
marcie_glicksman [2022/12/06 15:46]
pamela 		marcie_glicksman [2022/12/06 16:11] (current)
pamela [Therapeutic Drug Development Crossing Blood Brain Barrier]
Line 4: Line 4:
 {{ ::marcie_glicksman_-_orig3n_-_harvard.png?200|}} {{ ::marcie_glicksman_-_orig3n_-_harvard.png?200|}}
 Dr. Marcie Glicksman received her Bachelor’s degree from Brown University in Providence, Rhode Island and her Ph.D. in neuroscience from [[:Washington University]] in St. Louis, Missouri.  Dr. Marcie Glicksman received her Bachelor’s degree from Brown University in Providence, Rhode Island and her Ph.D. in neuroscience from [[:Washington University]] in St. Louis, Missouri. 
-(WU is known for **Monsanto**'s global HQ & academic partners)+(WU is known for **Monsanto**'s global HQ & academic partners eg Danforth Center)
  
 Dr. Glicksman has been in the field of drug discovery for 18 years, the most recent five in academics and thirteen years in the pharmaceutical/biotech industry, having worked at [[:Cephalon]], [[:DuPont]] - [[:Merck]], [[:Cubist]] (as director of leads discovery), and the start up company, [[:Descartes Therapeutics]].  Dr. Glicksman has been in the field of drug discovery for 18 years, the most recent five in academics and thirteen years in the pharmaceutical/biotech industry, having worked at [[:Cephalon]], [[:DuPont]] - [[:Merck]], [[:Cubist]] (as director of leads discovery), and the start up company, [[:Descartes Therapeutics]]. 
Line 13: Line 13:
  
 She has extensive experience in **assay development, high throughput screening, and chemical databases** as well as animal [[:pharmacology]] and preclinical development. ((https://web.archive.org/web/20221206141139/https://www.science.org/content/author/marcie-glicksman-phd)) She has extensive experience in **assay development, high throughput screening, and chemical databases** as well as animal [[:pharmacology]] and preclinical development. ((https://web.archive.org/web/20221206141139/https://www.science.org/content/author/marcie-glicksman-phd))
 +
 +==== Therapeutic Drug Development Crossing Blood Brain Barrier ====
 +The EnClear Team | www. encleartherapies.com/copy-of-the-enclear-team 
 +
 +Head of Biology Marcie Glicksman, PhD For the past 30 years, Dr. Glicksman has been dedicated to developing better therapeutics for the nervous system and other therapeutic areas. Her efforts have resulted in 8 drugs entering the clinic, **2 marketed drugs** resulting in over **$2B in sales** for [[:Cephalon]] (now Teva Pharmaceuticals) and [[:Cubist]] (now Merck). ((https://web.archive.org/web/20220524183432/https://www.encleartherapies.com/programs-copy))
 +
 +Our strategy is two-fold: 1) Lead with neuro-[[:oncology]] and help patients with Leptomeningeal Carcinomatosis.
 +2) Leveraging partnerships to expand into **neurodegenerative, lysosomal storage & autoimmune diseases**.
 +
 +Therapeutics targeting CNS disorders are ineffective at reaching critical areas of the CNS through traditional means to be efficacious.
 +Difficulty delivering past the [[:Blood Brain Barrier]], Blood-CSF, and Blood Arachnoid barriers.
 +Difficulty delivering to localized areas in the CNS
 +Increased dosing required to get to efficacious levels
 +Higher risk of peripheral toxicity and severe side effects
 +With EnClear's CSF Health Platform, therapeutics can be moved from specialized hospitals to local **infusion clinics**.((https://web.archive.org/web/20220524183621/https://www.encleartherapies.com/csf-health-platform))
  
  
Back to top